Equine/Horse Herpesvirus Type I glycoprotein E (important) antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) antibodies pairs and antigen for animal health (animal Equine/Horse infectious disease Equine/Horse Herpes Myeloencephalopathy) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Equine/Horse disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P137-Tg002-Ag01	Recombinant Equine/Horse Herpesvirus Type I glycoprotein E (important) protein	$3090.00
GMP-VT-P137-Tg002-Ab01	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P137-Tg002-Ab02	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P137-Tg002-Ab03	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) human monoclonal antibody (mAb)	$3090.00
GMP-VT-P137-Tg002-Ab04	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P137-Tg002-Ag01
Product Name	Recombinant Equine/Horse Herpesvirus Type I glycoprotein E (important) protein
Pathogen	Equine/Horse Herpesvirus Type I
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Equine/Horse Herpesvirus Type I level test of animal Equine/Horse infectious disease with Equine/Horse Herpes Myeloencephalopathy.
Tag	His
Product description	Recombinant Equine/Horse Herpesvirus Type I glycoprotein E (important) proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P137-Tg002-Ab01,GMP-VT-P137-Tg002-Ab02
Pathogen	Equine/Horse Herpesvirus Type I
Product Name	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine/Horse Herpesvirus Type I glycoprotein E (important) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus Type I antibodies in Equine/Horse Herpesvirus Type I level test of animal Equine/Horse infectious disease with Equine/Horse Herpes Myeloencephalopathy.
Product description	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus Type I antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P137-Tg002-Ab03,GMP-VT-P137-Tg002-Ab04
Pathogen	Equine/Horse Herpesvirus Type I
Product Name	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Equine/Horse Herpesvirus Type I glycoprotein E (important) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus Type I antibodies in Equine/Horse Herpesvirus Type I level test of animal Equine/Horse infectious disease with Equine/Horse Herpes Myeloencephalopathy.
Product description	Anti-Equine/Horse Herpesvirus Type I glycoprotein E (important) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

EHV-1 is a highly infectious virus that can cause significant morbidity and mortality in horses worldwide. As a member of the family Herpesviridae and the subfamily Alphaherpesvirinae, EHV-1 has a relatively simple structure compared to other viruses. Its genome consists of linear, double-stranded DNA, which is enclosed within an icosahedral capsid. The capsid is surrounded by a lipid envelope containing glycoproteins that facilitate attachment and entry into host cells.

EHV-1 has several major genes and proteins that play critical roles in infection and pathogenesis. Two of the most important proteins are glycoprotein B (gB) and glycoprotein D (gD), which are involved in attaching to and entering host cells. gB is a large transmembrane glycoprotein that forms spikes on the viral surface and mediates virus-cell fusion. In contrast, gD is a smaller, extracellular protein that binds to receptors on the host cell surface and triggers the fusion process. Other important genes and proteins include genes encoding DNA polymerase, thymidine kinase, immediate early proteins, and late structural proteins.

EHV-1 typically infects horses younger than five years old and can be transmitted via direct contact with nasal secretions, respiratory droplets, or contaminated surfaces. The virus initially replicates in the respiratory tract and spreads to regional lymph nodes before disseminating throughout the body. The clinical signs of EHV-1 infection can vary depending on the route of transmission, the horse's age, and its immune status.

The most severe disease caused by EHV-1 in horses is equine herpesvirus myeloencephalopathy (EHM), which is characterized by neurological symptoms such as ataxia, weakness, and paralysis. EHM is a form of encephalitis that results from the virus spreading to the central nervous system (CNS). In some cases, EHM can lead to permanent neurologic deficits or death. EHV-1 can also cause respiratory disease, which is often mild and self-limiting, but can progress to pneumonia in some cases. Pregnant mares infected with EHV-1 can develop abortion or deliver weak or stillborn foals.

The diagnosis of EHV-1 infection can be challenging, as clinical signs may be nonspecific, and several other equine pathogens can cause similar symptoms. Several diagnostic methods have been developed to detect EHV-1 infection in horses. PCR is a highly sensitive method that can detect viral nucleic acid in clinical samples such as nasal swabs, blood, or cerebrospinal fluid. The region of the virus targeted by PCR often includes the genes encoding gB and DNA polymerase. Virus isolation is another method that involves growing the virus in culture and using antibodies to identify it. Serology can detect antibodies against EHV-1 in the horse's blood, indicating past exposure or current infection. ELISA is an example of a protein-based diagnostic test that targets the gD protein and can be used to detect antibodies against EHV-1.

Effective management of EHV-1 infection in horses relies on a multimodal approach that includes vaccination, biosecurity measures, and appropriate antiviral therapy. Several vaccines are available that can provide partial protection against EHV-1 infection and reduce the severity of clinical signs. Biosecurity measures such as quarantining infected horses and disinfecting stables and equipment can help prevent the spread of the virus. Antiviral therapy remains experimental, and no specific drug has yet been approved for the treatment of EHV-1 infection in horses.

In conclusion, EHV-1 is a highly infectious virus that can cause significant morbidity and mortality in horses. Its structure, genes, and proteins are essential for viral replication and pathogenesis. The clinical signs of EHV-1 infection can vary depending on the horse's age, immune status, and route of transmission. Several diagnostic methods are available to detect EHV-1 infection in horses, including PCR, virus isolation, and serology. Effective management of EHV-1 infection relies on a combination of vaccination, biosecurity measures, and appropriate antiviral therapy.

About GDU